How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies
Antoni Ribas, Madhav V. Dhodapkar, Katie M. Campbell, Faith E. Davies, Steven D. Gore, Ronald Levy, Lee M. Greenberger
Abstract
Patients with hematologic malignancies are particularly vulnerable to COVID-19 infections, and upon a pooled data analysis of 24 publications, there is evidence that they have suboptimal antibody responses to COVID-19 vaccination and boosters. To provide them the needed additional protection from COVID-19, it is imperative to achieve a 100% full immunization rate in health care workers and adult caretakers, and to foster research to test higher doses and repeated rounds of COVID-19 vaccines and the use of passive immune prophylaxis and therapy.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)MedicineVaccinationImmunization2019-20 coronavirus outbreakImmunologyAntibodyIntensive care medicineVirologyInternal medicineOutbreakDiseaseInfectious disease (medical specialty)COVID-19 and healthcare impactsSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies